RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Clinical trial NCT04827862 · COMPLETED
Trial details
- NCT number
- NCT04827862
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2026-05-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.